| Timothy Curley, MD | |
|
85 Seymour St, Ste 900, Hartford, CT 06106-5501 | |
| (860) 241-0700 | |
| (860) 525-7881 |
| Full Name | Timothy Curley |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 27 Years |
| Location | 85 Seymour St, Hartford, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952400970 | NPI | - | NPPES |
| 06144079003 | Medicaid | CT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 033821 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Starling Physicians, Pllc | 7517863749 | 204 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
Research suggests that a gene that governs the body's biological clock acts differently in males versus females and may protect females from heart disease.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
The winners of the London Health Commission Awards were announced last night at City Hall. The winners were all small community-based organisations.
Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.
› Verified 1 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407806391 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000700 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
Research suggests that a gene that governs the body's biological clock acts differently in males versus females and may protect females from heart disease.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
The winners of the London Health Commission Awards were announced last night at City Hall. The winners were all small community-based organisations.
Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.
› Verified 1 days ago
| Entity Name | Hartford Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770696643 PECOS PAC ID: 2567366016 Enrollment ID: O20031125000752 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
Research suggests that a gene that governs the body's biological clock acts differently in males versus females and may protect females from heart disease.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
The winners of the London Health Commission Awards were announced last night at City Hall. The winners were all small community-based organisations.
Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.
› Verified 1 days ago
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
Research suggests that a gene that governs the body's biological clock acts differently in males versus females and may protect females from heart disease.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
The winners of the London Health Commission Awards were announced last night at City Hall. The winners were all small community-based organisations.
Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Timothy Curley, MD 2110 Silas Deane Hwy, Rocky Hill, CT 06067-2313 Ph: (860) 258-3400 | Timothy Curley, MD 85 Seymour St, Ste 900, Hartford, CT 06106-5501 Ph: (860) 241-0700 |
News Archive
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.
Research suggests that a gene that governs the body's biological clock acts differently in males versus females and may protect females from heart disease.
InterMune, Inc. today announced that it has submitted an electronic New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Pirfenidone has been granted Orphan Drug and Fast Track designation by the FDA, and also has been granted Orphan Drug status in Europe.
The winners of the London Health Commission Awards were announced last night at City Hall. The winners were all small community-based organisations.
Pancreatic cancer, which affects about 60,000 Americans every year, is one of the deadliest forms of cancer. After diagnosis, fewer than 10 percent of patients survive for five years.
› Verified 1 days ago
Gagandeep Singh, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 114 Woodland St, Hartford, CT 06105 Phone: 860-714-7446 Fax: 860-714-1508 | |
Yixia Ye, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 31 Seymour St Ste 205, Hartford, CT 06106 Phone: 860-524-2610 | |
Andrew P Scatola, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 85 Jefferson Street, Hartford Hospital Cardiology Dept, Hartford, CT 06106 Phone: 860-972-1212 | |
Dr. David Jay Altszuler, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 85 Seymour St Ste 719, Hartford, CT 06106 Phone: 860-522-0604 Fax: 860-522-0604 | |
Dr. Nisha Dhanabalsamy, MBBS Nephrology Medicare: Accepting Medicare Assignments Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-972-0549 | |
Sindhuja Palle, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06106 Phone: 860-545-5000 | |
Dr. Jamie Matthew Roche, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 80 Seymour St, Hartford, CT 06102 Phone: 860-545-3359 |